Search

Displaying results 341 - 350 of 1342 in total
  1. Indication

    Transient Ischemic Attack

    go.drugbank.com/conditions/DBCOND0029275
    Drugs: Acenocoumarol · Acetylsalicylic acid · Atorvastatin · Dipyridamole · Glycine · Nicergoline +2 more
    Synonyms: TIA, TIA, Brain
  2. Drug

    Ethinylestradiol

    go.drugbank.com/drugs/DB00977
    ApprovedInvestigational

    Ethinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering. It was developed in an effort to create an estrogen with greater oral bioavailability. These properties were achieved by the substitu...

    Mixtures: PIL KB HARMONIS, PIL KB I KOMBINASI
  3. Drug

    Reslizumab

    go.drugbank.com/drugs/DB06602
    ApprovedInvestigational

    IL-5 is a pro-inflammatory cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils [FDA Label]. … By targeting the IL-5 and disrupting its signalling pathways, reslizumab aims to inhibit eosinophil maturation and promote programmed cell death [A31578].

  4. Indication

    Relapsed CD22-positive B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

    go.drugbank.com/conditions/DBCOND0165828
    Drugs: Inotuzumab ozogamicin
    Synonyms: Relapsed CD22-positive B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
  5. Drug

    Oprelvekin

    go.drugbank.com/drugs/DB00038
    ApprovedInvestigationalWithdrawn

    Oprelvekin, the active ingredient in Neumega®, is recombinant Interleukin-11 (IL-11), which is produced in Escherichia coli (E. coli) by recombinant DNA technology. … With a molecular mass of approximately 19,000 daltons, the non-glycosylated protein is 177 amino acids in length in comparison to the natural IL-11, which is 178 amino acid long.

    Synonyms: IL-11
  6. Drug

    Guselkumab

    go.drugbank.com/drugs/DB11834
    ApprovedInvestigational

    IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation [A20357].

  7. Drug

    Indium In-111 oxyquinoline

    go.drugbank.com/drugs/DB09473
    Approved

    Following intravenous administration, the lipid-soluble complex is able to penetrate platelet cell membranes.

  8. Drug

    Beeswax

    go.drugbank.com/drugs/DB11600
    Approved

    Beeswax is used as a stiffening agent in ointments and creams, and enables water to be incorporated to produce water-in-oil emulsions.

  9. Drug

    Tocilizumab

    go.drugbank.com/drugs/DB06273
    ApprovedInvestigational

    Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. … [L12789] It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies.

  10. Drug

    Pine needle oil (pinus mugo)

    go.drugbank.com/drugs/DB11276
    Approved

    Pine needle oil is obtained from the needles of *Pinus mugo* tree via steam distillation. … Major components of pine needle oil (pinus mugo) include α-Pinene, β-pinene, δ-3-carene, limonene, β-phellandrene, (E)-caryophyllene, and germacrene D.

    Synonyms: Dwarf pine oil, Oil, dwarf pine